Clinical Trials Browser

Phase 2 × Terminated × duvelisib × Clear all

NCT04209621 2022-03-09

Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2 Terminated

3 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell